Blood Biomarkers in Major Depression

Depression is a leading cause of disability worldwide, affecting nearly 16% of the general population. Its physiopathology remains unclear. Based on gene-environment studies and epigenetic studies, a main hypothesis proposed that the major depressive episode (MDE) results from the convergence of multiple factors including biological factors such as multi-genic vulnerability, hormonal and immunological variations as well as environmental factors. As a consequence, mRNA could define a biological signature of the MDE.

A pan-genomic screen by blood prelevement and psychometric data collection will be set-up on a subset of MDE and control samples to identify mRNA candidates for a transcriptional signature of MDE,

a pan genomic screening by blood prelevement and psychometric data collection wil be performed on healthy subject

The major aim of our study is to compare the expression level of selected genes between patient suffering from major depression and control subjects and within patients across the MDE evolution. We plan to describe a transcriptional signature of the MDE.

evaluate the role played by confounding factors as genetic polymorphisms to distinguish bipolar from unipolar depression

evaluate the role played by confounding factors as immune phenotype to distinguish bipolar from unipolar depression

evaluate the role played by confounding factors as psychotropic medications to distinguish bipolar from unipolar depression

Inclusion Criteria: Major depressive disorder at inclusion according to the DSM IV at the time of the inclusion, Having a score on the scale of depression of Hamilton ( HDRS-17) > 19 at the time of the inclusion, Taken care by a grown-up psychiatric department, that the coverage(care) is realized in ambulatory or during a hospitalization Exclusion Criteria: Schizophrenia

Belzeaux R, Gorgievski V, Fiori LM, Lopez JP, Grenier J, Lin R, Nagy C, Ibrahim EC, Gascon E, Courtet P, Richard-Devantoy S, Berlim M, Chachamovich E, Theroux JF, Dumas S, Giros B, Rotzinger S, Soares CN, Foster JA, Mechawar N, Tall GG, Tzavara ET, Kennedy SH, Turecki G. GPR56/ADGRG1 is associated with response to antidepressant treatment. Nat Commun. 2020 Apr 2;11(1):1635. doi: 10.1038/s41467-020-15423-5.